Trial Profile
A phase III pivotal, multicenter, double-blind, randomized, placebo-controlled study of milnacipran for the treatment of fibromyalgia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2020
Price :
$35
*
At a glance
- Drugs Milnacipran (Primary)
- Indications Fibromyalgia; Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 24 Oct 2020 Results of two large analgesic clinical trials (NCT00098124 and NCT00436033) for the treatment of fibromyalgia to evaluate the utility of different pain indices for detecting intervention effects, published in the Journal of Pain
- 20 May 2009 Additional reference added (1132643) relating to published results from 162nd Annual Meeting of the American Psychiatric Association.
- 07 May 2009 Results presented at the 28th Annual Scientific Meeting of the American Pain Society (APS 2009).